Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule IV
1200-1600 mg/day PO divided q6-8hr; not to exceed 2.4 g/day
400 mg PO before the procedure
CrCl 10-50 mL/min: Change frequency of administration to every 9-12hr
CrCl <10 mL/min: Change frequency of administration to 12-18hr
Dosage Forms & Strengths
tablet: Schedule IV
<6 years old: Not recommended
6-12 years old: 100-200 mg PO q8-12hr
>12 years old: 1200-1600 mg/day PO divided q8-12hr; not to exceed 2.4 g/day
200 mg PO prior to procedure
Not drug of choice in elderly because of potential physical and psychological dependence
Use lowest effective dose to avoid oversedation
Lower initial dose; adjust more gradually; 200 mg PO q8-12hr
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
- Abnormal ECG, palpitations, tachyarrhythmia
- Asthenia, ataxia, dizziness, EEG abnormality, euphoria, fast, excitement, paradoxical, headache, paresthesia, slurred speech, somnolence, vertigo
- Hives, maculopapular eruption, erythematous
- Diarrhea, nausea, vomiting
- Disorder of accommodation (ocular)
- Cardiac dysrhythmia, hypotension crisis, syncope
- Bullous dermatosis (rare), Stevens-Johnson syndrome (rare)
- Agranulocytosis, aplastic anemia, leukopenia
- Anaphylaxis (rare)
Hypersensitivity, allergy to related drugs (eg, carisoprodol)
History of porphyria
Hypersensitivity may occur
May impair physical or mental abilities due to CNS depression
Secreted into breast milk; avoid during breastfeeding
Caution in patientw with depression or suicidal tendencies
Caution in hepatic/renal impairment or seizure disorder
Pregnancy & Lactation
Pregnancy Category: D
Lactation: secreted into breast milk at 2-4x plasma concentration; avoid
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Carbamate derivative; inhibitory effects in thalamus, limbic system; may inhibit multineural spinal reflexes
Mild sedative, anticonvulsant, muscular relaxant effects
Absorption: well-absorbed from GI tract
Half-Life: 6-16 hr
Onset: <1 hr
Peak plasma time: 1-3hr
Peak plasma concentration: 5-30 mcg/mL (400 mg dose)
Protein Bound: 20%
Excretion: Urine (8-20%); feces (10%)
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.